Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

GammaCore is both effective and cost effective for the treatment of cluster headache

May 17, 2016 By Nic Abraham

gammaCore S Product- With Caps 1A paper in the Journal of Headache and Pain reports that non-invasive stimulation of the vagus nerve (nVNS) is a cost effective therapy for cluster headache.  These findings were based on reductions in medication use and improvements in quality of life.  The publication also notes that further economic benefits would have been found had reduced visits to clinics been taken into account.

Cluster headache, which is considered one of the worst pain conditions known to medical science, has no approved therapies to prevent its attacks. The publication notes, “the treatment of cluster headache is challenging and many of the commonly used preventive medications are associated with serious safety risks, poor tolerability, and/or marginal efficacy.”

The findings in this publication follow from the successful PREVA trial, which involved 97 patients at ten sites across Europe. The patients were randomized into two arms – one using the gammaCore device plus the standard of care, and the other the standard of care alone. 40% of patients using gammaCore in addition to the standard of care had a ≥50% reduction in the number of weekly cluster headache attacks compared with 8% (p<0.001) in patients treated with the standard of care alone.  

The lead investigator of the PREVA trial, Dr. Charly Gaul, Head of the Migraine and Headache clinic Königstein, Germany stated, “It has been previously shown that gammaCore is an effective preventative against cluster attacks, but now we can see that it also reduces costs.”

In addition to the primary endpoint, i.e., reduction in attack frequency, the PREVA study also collected a variety of quality of life and economic measures, which permitted the modelling of cost-effectiveness reported on in this publication.  The current paper highlights a 25% reduction in costs associated with acute treatments such as zolmitriptan, sumatriptan and inhaled oxygen, which led to a savings in medication usage of approximately €1,736 per patient per year, and an average total cost savings of €2,799 per patient per year.  In all scenarios modelled, nVNS was more cost-effective than the current standard practice.

electroCore
www.electrocore.com

Related Articles Read More >

A portrait of Dr. Philip Adamson
Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
gBETA Medtech accelerator picks its next startups
Fresenius Medical Care
FDA warns of potential toxic risk from Fresenius hemodialysis machines

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech